Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slavinorm for Lower Extremity Atherosclerotic Arterial Occlusive Disease
NCT05933720Recruiting
- Sponsor
- Ryazan State Medical University
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of Slavinorm in Peripheral Arterial Disease (PAD) (4 arms), sponsored by Ryazan State Medical University. Primary endpoints: Lower artery or bypass graft thrombosis at 1 year, Disease progression at 1 year and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
Slavinorm
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT05933720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933720.